Massive study seeks 50,000 to unlock Alpha-1 secrets
NCT ID NCT00500123
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to learn more about alpha-1 antitrypsin deficiency, a genetic condition that can affect the lungs and liver. Researchers will enroll up to 50,000 people who are at risk due to symptoms or family history. Participants will complete questionnaires to help track health outcomes and understand the risks and benefits of genetic testing.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALPHA 1-ANTITRYPSIN DEFICIENCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Florida
RECRUITINGGainesville, Florida, 32610, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI model could predict who needs a lung transplant for rare emphysema
- Could a simple shot replace IV drips for Alpha-1 patients?
- Hidden liver harm: study tracks silent damage in genetic disorder
- Promising liver drug trial halted early: what it means for patients
- Gene-Editing shot aims to fix lung and liver damage in rare disease
- New drug AIR-001 enters first human tests for rare lung condition